Skip to content
Subscriber Only

U.S. Ends Deal for Lilly Single Antibody to Focus on Combo

A treatment of the single antibody Bamlanivimab.

A treatment of the single antibody Bamlanivimab.

Photographer: Boston Globe/Getty Images

Updated on

Eli Lilly & Co. said U.S. health officials canceled a deal for doses of its single antibody drug for Covid-19 to focus on the drugmaker’s combination treatment.

The U.S. government terminated its agreement for 350,856 remaining doses of bamlanivimab, the single antibody, that were scheduled to be delivered by the end of March 2021, Lilly said Monday in a statement. Their agreement was modified to focus on the supply of the combination of that drug and etesevimab, another antibody against the coronavirus.